Answers are grounded in this paper and cite their sources.
In this study, we synthesized some new benzimidazole–Schiff base hybrids ( 5a–5k ) and characterized them using nuclear magnetic resonance (NMR) and mass spectral methods. The in vitro α-glucosidase inhibitory activities of compounds 5a–5k were investigated. Notably, all compounds ( 5a–5k ) exhibited higher inhibition (IC 50 = 0.52–14.65 µM) than the standard drug acarbose (IC 50 = 45.3 µM), highlighting their significant α-glucosidase inhibitory potential. Within the series, compound 5i demonstrated the greatest activity with the lowest IC 50 value (0.52 µM), whereas 5k exhibited the lowest activity (IC 50 value of 14.65 µM). Molecular docking ( 5a–5k ) against Saccharomyces cerevisiae isomaltase (PDB: 3A4A) revealed favorable binding affinities, with docking scores ranging from −8.2 to −10.9 kcal/mol, exceeding that of acarbose (−8.8 kcal/mol) for several compounds. Compound 5i showed optimum binding affinity (−10.9 kcal/mol), forming several π–π, π–alkyl, π–anion, and H-bonds containing significant catalytic residues. Compounds 5e , 5h , and 5j demonstrated significant binding due to the substantial hydrophobic and electrostatic interactions inside the enzyme active site. Steady-state kinetic studies revealed that compound 5i is a potent competitive inhibitor of α-glucosidase, as shown by the Lineweaver–Burk plots displaying a common intercept with unchanged Vmax and improved apparent K m values. The secondary plot gave a K i value of 5.0 µM, representing the robust binding affinity of 5i toward free enzyme and higher affinity as related to the native PNPG substrate.
No takes yet. Share an insight, caveat, or question.
SWAMY et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: